Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome

• Status: Approved for marketing
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Treatments: 3,4-diaminopyridine; 4-Aminopyridine; Amifampridine

Criteria

Inclusion Criteria:

• Age 18 years or older,

• Diagnosed with LEMS,

• If female, have a negative pregnancy test, and

• If premenopausal, be willing to practice an effective form of birth control during the study,

• Tested and found by ECG not to have a prolonged QT syndrome,

• Agree to have a second ECG at the time of peak drug effect,

• Has understood and signed the Informed Consent.

Exclusion Criteria:

• Is known to have a sensitivity to 3, 4-DAP,

• Has a history of:

1. past or current seizures,

2. cardiac arrhythmia,

3. hepatic, renal or hematologic disease, or

4. severe asthma,

• Is believed by the investigator to be unable to comply with the protocol.